"evaluation and testing services (ETS) for vaccines and other biologics for infectious diseases.
Active Indefinite Delivery Contract Awarded
- Contract number
- 75N93025D00025
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Evaluation and testing services (ETS) for vaccines Solicitation · Posted Jun 21, 2024
- Last date to order 11% complete
- IDV ceiling
- $136,588,701.00
- Maximum order
- $136,588,701.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 37 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corporation. The $136.6 million contract is for the provision of evaluation and testing services (ETS) for vaccines and other biologics targeting infectious diseases.
The contract has a single award structure and a period of performance running through September 2035. Based on DVC's prior federal awards, the contracted services are likely to include preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and current Good Manufacturing Practice (cGMP) production in support of therapeutics and vaccines for emerging infectious diseases. The contract does not utilize any set-asides, and performance will primarily occur at DVC's facilities in Maryland. This IDC builds upon DVC's existing portfolio of NIAID-funded infectious disease-focused contracts, including a $30 million IDIQ for preclinical services and a $36 million contract for diagnostic development.
Quick answers
Who was awarded contract 75N93025D00025?
75N93025D00025 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2025.
How much is contract 75N93025D00025 worth?
75N93025D00025's own ceiling is $136,588,701. A single order can be worth up to $136,588,701.
Who can order from contract 75N93025D00025?
75N93025D00025 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93025D00025 competed?
The extent of competition for 75N93025D00025 was full and open competition. The government received 37 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV